AVALO THERAPEUTICS, INC. Amortization of Debt Discount (Premium)
AVALO THERAPEUTICS, INC. (AVTX) reported Amortization of Debt Discount (Premium) of $0 for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-20.
Financial Statements › Cash Flow › Operating Activities
us-gaap:AmortizationOfDebtDiscountPremium · last filed 2025-03-20
- AVALO THERAPEUTICS, INC. amortization of debt discount (premium) for the quarter ending 2024-12-31 was $0.00.
- AVALO THERAPEUTICS, INC. amortization of debt discount (premium) for the quarter ending 2024-09-30 was $0.00, a 100.00% decline year-over-year.
- AVALO THERAPEUTICS, INC. amortization of debt discount (premium) for the quarter ending 2024-06-30 was $0.00, a 100.00% decline year-over-year.
- AVALO THERAPEUTICS, INC. amortization of debt discount (premium) for the quarter ending 2024-03-31 was $0.00, a 100.00% decline year-over-year.
- AVALO THERAPEUTICS, INC. amortization of debt discount (premium) for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- AVALO THERAPEUTICS, INC. amortization of debt discount (premium) for fiscal 2023 was $1.83M, a 31.61% increase from fiscal 2022.
- AVALO THERAPEUTICS, INC. amortization of debt discount (premium) for fiscal 2022 was $1.39M, a 74.94% increase from fiscal 2021.
- AVALO THERAPEUTICS, INC. amortization of debt discount (premium) for fiscal 2021 was $794.00K.
| Period end | Amortization of Debt Discount (Premium) 3 month | Amortization of Debt Discount (Premium) 6 month | Amortization of Debt Discount (Premium) 9 month | Amortization of Debt Discount (Premium) 12 month |
|---|---|---|---|---|
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $0.00 derived: sum of 2 quarters · filed 2025-03-20 | $0.00 derived: sum of 3 quarters · filed 2025-03-20 | $0.00 10-K · filed 2025-03-20 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $0.00 derived: sum of 2 quarters · filed 2024-11-07 | $0.00 10-Q · filed 2024-11-07 | $0.00 derived: sum of 4 quarters · filed 2025-03-20 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q/A 3 month · filed 2024-08-12 | $0.00 10-Q · filed 2024-08-12 | $0.00 derived: sum of 3 quarters · filed 2025-03-20 | $1.13M derived: sum of 4 quarters · filed 2025-03-20 |
| 2024-03-31 | $0.00 10-Q/A · filed 2024-07-11 | $0.00 derived: sum of 2 quarters · filed 2025-03-20 | $1.13M derived: sum of 3 quarters · filed 2025-03-20 | $1.48M derived: sum of 4 quarters · filed 2025-03-20 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $1.13M derived: sum of 2 quarters · filed 2025-03-20 | $1.48M derived: sum of 3 quarters · filed 2025-03-20 | $1.83M 10-K · filed 2025-03-20 |
| 2023-09-30 | $1.13M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $1.48M derived: sum of 2 quarters · filed 2024-11-07 | $1.83M 10-Q · filed 2024-11-07 | $2.18M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $349.00K derived: 10-Q 6 month − 10-Q/A 3 month · filed 2024-08-12 | $699.00K 10-Q · filed 2024-08-12 | $1.05M derived: sum of 3 quarters · filed 2024-08-12 | $1.40M derived: sum of 4 quarters · filed 2024-08-12 |
| 2023-03-31 | $350.00K 10-Q/A · filed 2024-07-11 | $699.00K derived: sum of 2 quarters · filed 2024-07-11 | $1.05M derived: sum of 3 quarters · filed 2024-07-11 | $1.39M derived: sum of 4 quarters · filed 2024-07-11 |
| 2022-12-31 | $349.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | $703.00K derived: sum of 2 quarters · filed 2024-03-29 | $1.04M derived: sum of 3 quarters · filed 2024-03-29 | $1.39M 10-K · filed 2024-03-29 |
| 2022-09-30 | $354.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $690.00K derived: sum of 2 quarters · filed 2023-11-09 | $1.04M 10-Q · filed 2023-11-09 | $1.39M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $336.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $686.00K 10-Q · filed 2023-08-03 | $1.03M derived: sum of 3 quarters · filed 2023-08-03 | $1.38M derived: sum of 4 quarters · filed 2023-08-03 |
| 2022-03-31 | $350.00K 10-Q · filed 2023-05-04 | $699.00K derived: sum of 2 quarters · filed 2023-05-04 | $1.04M derived: sum of 3 quarters · filed 2023-05-04 | $1.14M derived: sum of 4 quarters · filed 2023-05-04 |
| 2021-12-31 | $349.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | $690.00K derived: sum of 2 quarters · filed 2023-03-29 | $794.00K derived: sum of 3 quarters · filed 2023-03-29 | $794.00K 10-K · filed 2023-03-29 |
| 2021-09-30 | $341.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | $445.00K derived: sum of 2 quarters · filed 2022-11-07 | $445.00K 10-Q · filed 2022-11-07 | $445.00K derived: sum of 4 quarters · filed 2022-11-07 |
| 2021-06-30 | $104.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $104.00K 10-Q · filed 2022-08-04 | $104.00K derived: sum of 3 quarters · filed 2022-08-04 | $104.00K derived: sum of 4 quarters · filed 2022-08-04 |
| 2021-03-31 | $0.00 10-Q · filed 2022-05-05 | $0.00 derived: sum of 2 quarters · filed 2022-05-05 | $0.00 derived: sum of 3 quarters · filed 2022-05-05 | |
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-02 | $0.00 derived: sum of 2 quarters · filed 2022-03-02 | $0.00 10-K · filed 2022-03-02 | |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $0.00 10-Q · filed 2021-11-09 | ||
| 2020-06-30 | $0.00 10-Q · filed 2021-08-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |